ABL Wealth Advisors LLC

Fees and Compensation
The firm provides investment management and investment advisory services for a fee. This fee is
typically charged as a percentage of assets under our management. Although this fee is typically
expressed as an annual percentage, it is calculated based on the market value of the account at
month end, quarter end or based on an average and generally invoiced on a monthly or quarterly
basis in arrears. In some cases, the Firm may hire Sub-Advisers and pay such Sub-Advisers
management fees from our management fees, or our fees may be net of underlying fees/expenses
of the Sub-Advisers and/or Underlying Funds to which we allocate, depending on the
circumstances. Market values are sourced from the accounting systems of service providers unless
specifically directed otherwise by the client. All fees paid to the Firm are separate from any fees
and expenses that are charged by pooled funds to shareholders of fund shares (for accounts that
hold shares of pooled funds). A complete explanation of expenses charged by the pooled fund is
contained in each fund's disclosure documents. Our institutional client investment management
and advisory fees range from 3 to 150 bps depending on the investment objectives and the dollar
amount of the investment.

Investment Company Management

The Firm charges the ABX Longevity Growth & Income Fund (the “Registered Fund”) a
management fee at the rate of 1.45% per annum of the average daily assets under management as
determined in accordance with the management fee calculation formula set forth in the Registered
Fund’s prospectus. The Firm’s management fee will be collected monthly in arrears approximately
ten (10) days following the close of each calendar month. The management fee will be charged to
the Registered Fund based upon the number of days in the month divided by the number of days
in the year. The Firm’s management fee will be indirectly borne by the Registered Fund’s
shareholders as a result of their holdings of shares in the Registered Fund. The Firm is obligated to
pay expenses associated with providing the services stated in the Investment Management
Agreement, including compensation of its officers and
employees connected with investment and economic research, trading and investment
management and administration of the Registered Fund. The fund is responsible for covering the
costs of services provides that it has agreements with, as well as other expenses related to its
operation, including custodian and transfer agent fees and charges, brokerage costs, taxes, and
expenses tied to Longevity Assets acquired for the Registered Fund and any associated losses
incurred in connection therewith.

All other details of the investment management and other fees applicable to the Registered Fund
are set forth in detail in the prospectus for the Registered Fund.

The Firm is a fee-only investment advisor. No commissions or asset-based sales charges are
received from the purchase of individual securities or other investment products in order to
eliminate the potential for conflict of interests.

Performance-Based Fees and Side-by-Side Management
The Firm does not charge performance-based fees or participate in side-by-side management.

Types of Clients
The Firm currently provides investment management services to institutional investors, private funds,
and registered investment funds.

Methods of Analysis, Investment Strategies, and Risk of Loss
Methods of Analysis and Investment Strategies

The Firm invests primarily in Longevity Assets. The Firm’s objective is to seek long-term capital
appreciation by investing in a diversified portfolio of life insurance policies, annuities, insurance
linked investments, public securities and debt offerings, private investments including credit
opportunities, and other mortality related products. The Firm seeks to invest in high-quality
structured credit opportunities of various asset types, vintages, maturities, jurisdictions and capital
structure priorities, including debt and equity tranches of collateralized loan obligations (“CLOs”),
collateralized mortgage obligations (“CMOs”), commercial mortgage-backed securities
(“CMBS”), residential mortgage-backed securities (“RMBS”), consumer and commercial asset-
backed securities (“ABS”), structured finance products that invest in commercial and/or

consumer finance instruments and other forms of esoteric assets which may include but are not
limited to insurance-related assets, whole loans, regulatory capital relief transactions, or credit
default swaps in which protection is sold by an issuer of notes with respect to a portfolio of
corporate credits.

The Firm uses the technology provided by its affiliate, ABL Technologies, LLC (“ABL
Technologies”) to monitor the performance of its life insurance investments and adjust the portfolio
of Longevity Assets as needed to maximize the portfolio’s income and growth potential. By
leveraging this technology, the Firm will to identify and acquire Mortality Contracts that it believes
offer positive attractive risk-adjusted returns (priced at a discount to face value, while accounting
for the time-value of the invested capital and payment of expected premiums to service the
Mortality Contracts).

The Firm will also use Longevity Market Methodology™, proprietary portfolio market technology
of its affiliate, Longevity Market Technologies, LLC to support the valuation of certain Mortality
Contracts. The Longevity Market Methodology leverages its ability to quickly process large
probability models to better predict the mortality associated with Longevity Assets over a large set
of data metrics, which in turn assists with assessing the risk-versus-return distribution rating per
Longevity Asset. Of primary importance is the valuation of the assets, as well as intervals of
confidence around these values. We utilize a wide range of metrics to assess the risk level of each
life insurance policy, which may include, age, estimated life expectancy, estimated survival
probability, estimated maturity probability, discounts to face value, medical advancements and
market feedback. In accordance with each client’s investment policy, we thoroughly evaluate each
policy using the valuation metrics before making investment decisions. This process allows us to
identify policies that align with our client’s risk tolerance and investment objectives. By adhering
to this methodology, we aim to optimize our client’s portfolio composition and maximize client
returns. Of primary importance is the valuation of the assets, as well as intervals of confidence
around these values. We utilize a heatmap rating systemwide range of metrics to assess the risk
level of each policy, which may include, age, estimated life expectancy, estimated survival
probability, estimated maturity probability, discounts to face value, medical advancements and
market feedback. The heatmap assigns grades ranging from 1 to 5, with 1 indicating an investment
with lower breakeven risk and greater holding opportunity and 5 representing an investment with
higher breakeven risk due to an extended mortality experience and greater trade opportunity. In
accordance with each client’s investment policy, we thoroughly evaluate each policy using the
heatmap and other valuation metrics before making investment decisions. This process allows us
to identify policies that align with each client’s risk tolerance and investment objectives. By
adhering to this methodology, we aim to optimize our client’s portfolio composition and maximize
client returns.

The Firm, after considering advice from ABL Technologies determines to purchase, sell or hold a
Longevity Asset for a client based primarily upon the following considerations: (i) the difference
between market-place’s value of a Mortality Contract vs the valuation of a Mortality Contract, (ii)
the diversity of the client’s investment portfolio, and (iii) the client’s cash flow needs and excess
cash. The Firm, in coordination with ABL Technologies, plan to consider the following factors to
develop its estimate of the value of a Mortality Contract: (i) age of the insured, (ii) estimated life
expectancy of the insured, (iii) the life expectancy ratio of the insured (this is the ratio determined
by the estimated life expectancy of the insured as compared to the breakeven point of the
investment), (iv) the estimated survival probability as of the breakeven date of the insured, (v) the
estimated maturity probability (the estimated survival probability of the policies insured at which
the policy’s coverage expires), and (vi) expected return on capital investment based upon the
estimated purchase price (including any discount to face value payout for Mortality Contracts).

The methodologies developed by ABL Technologies also enable the Firm to deploy a dual criterion
evaluation system. The first criterion focuses on the valuation of Mortality Contracts using a
defined risk-adjusted market discount rate, coupled with a projected life expectancy. The second
criterion derives its valuation from the cost basis of the Mortality Contract and incorporates the
...